H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $267. The company’s shares closed on Friday at $130.80.
Chattopadhyay wrote:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.75, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.9%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 0.7% and a 45.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $207.06, a 58.3% upside from current levels. In a report issued on February 25, BTIG also reiterated a Buy rating on the stock with a $190 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $70.50. Currently, Sarepta Therapeutics has an average volume of 1.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
